Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Strong-Buy”

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at StockNews.com from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday.

Several other equities analysts have also recently issued reports on ESPR. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

Esperion Therapeutics Trading Up 2.5 %

Shares of Esperion Therapeutics stock traded up $0.05 during trading on Thursday, reaching $2.09. The company’s stock had a trading volume of 7,461,575 shares, compared to its average volume of 7,048,547. The company has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $2.07. The firm has a market cap of $395.85 million, a PE ratio of -0.99 and a beta of 0.89. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the previous year, the firm earned ($0.76) earnings per share. On average, analysts predict that Esperion Therapeutics will post -0.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the stock. Private Portfolio Partners LLC purchased a new stake in shares of Esperion Therapeutics during the 4th quarter worth $30,000. Herbst Group LLC purchased a new stake in shares of Esperion Therapeutics during the 1st quarter worth $28,000. CVI Holdings LLC purchased a new stake in shares of Esperion Therapeutics during the 1st quarter worth $37,000. Simplicity Wealth LLC purchased a new stake in shares of Esperion Therapeutics in the 1st quarter worth about $44,000. Finally, PSI Advisors LLC boosted its position in shares of Esperion Therapeutics by 161.5% in the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 10,500 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.